Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2018 Sep 10;19(1):e51–e61. doi: 10.1016/j.clml.2018.09.002

Figure 2: Outcomes according to disease response to chemotherapy.

Figure 2:

Local control (a), progression-free survival (b) and overall survival (c) of patients with chemo-sensitive disease (n=8) compared to those with chemo-refractory disease (n=15).